1 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 terminated. 4 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Tirzepatide Placebo: new trials by email Literature Review of Tirzepatide Placebo trials Research Report on Tirzepatide Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tirzepatide in Idiopathic Intracranial Hypertension Trial Tirzepatide, Tirzepatide Placebo - Idiopathic Intracranial Hypertension (IIH) | Phase 4 | Recruiting | Duke University | 60 | 2026-08-25 | 2026-09-15 |
| Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide - Obesity and Overweight | Phase 2 | Not yet recruiting | Biomed Industries, Inc. | 224 | 2026-08-15 | 2026-03-27 |
| A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes Bimagrumab, Tirzepatide, Bimagrumab Placebo - Obesity, Overweight | Phase 2 | Withdrawn | Eli Lilly and Company | 2025-05-23 | 2025-09-24 | |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Bimagrumab, Tirzepatide, Bimagrumab Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | 2024-10-21 | 2026-05-26 |
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide - Obesity | Phase 2 | Terminated | BioAge Labs, Inc. | 204 | 2024-06-27 | 2025-03-13 |
Obesity (4) · Overweight (3) · Platelet Glycoprotein IV Deficiency (2) · Diabetes Mellitus, Type 2 (1) · Headache (1) · Pseudotumor Cerebri (1)
Eli Lilly and Company (2) · BioAge Labs, Inc. (1) · Biomed Industries, Inc. (1) · Duke University (1)
United States (5) · Argentina (1) · Australia (1) · Canada (1) · China (1) · Japan (1) · New Zealand (1)
Alexa N Bramall, MD (1) · Lloyd Tran, PhD (1)